Cancer Immunotherapy relies on harnessing a patient's immune system to fine-tune specific
anti-tumor responses and ultimately eradicate cancer. Among diverse therapeutic …

CAR (Chimeric antigen receptor)-T cell therapy has become a very promising type of
immunotherapy against hematological cancers. This report is focused on CAR-T cells …

Chimeric antigen receptor (CAR) T cell therapy for solid tumors shows promise, but several
hurdles remain. Strategies to overcome barriers such as CAR T therapy-related toxicities …

Among the many oncology therapies, few have generated as much excitement as CAR-T.
The success of CAR therapy would not have been possible without the many discoveries …

Background Recent evidence suggests that B cells and autoantibodies have a substantial
role in the pathogenesis of Multiple sclerosis. T cells could be engineered to express …

Harnessing immune effector cells to benefit cancer patients is becoming more and more
prevalent in recent years. However, the increasing number of different therapeutic …

Mesenchymal stromal cells (MSCs) and chimeric antigen receptor (CAR)‐T cells are two
core elements in cell therapy procedures. MSCs have significant immunomodulatory effects …

Cell therapy utilizing chimeric antigen receptors (CARs) in conjunction with immune cells,
primarily T lymphocytes, is known as CAR-T cell therapy. This innovative approach is …

Synthetische Rezeptorbiologie als Werkzeug zur Erforschung von Zytokin- und
Wachstumsfaktorrezeptoren Entwicklung synthetischer Page 1 Aus dem Institut für …